進行性運動失調と筋力障害の世界市場レポート 2025年

進行性運動失調と筋力障害の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.0％で586億8,000万米ドルに成長します。予測期間の成長は、神経疾患の有病率の増加、慢性疾患の有病率の上昇、保険適用範囲の拡大、高齢化率の上昇に起因しています。予測期間における主要動向としては、技術の進歩、遺伝子検査、遺伝子治療、個別化医療、遠隔医療の導入などが挙げられます。

神経疾患の有病率の増加が進行性運動失調と筋力障害市場の成長を牽引すると予想されます。神経疾患は、脳、脊髄、神経、神経筋接合部などを含む中枢神経系と末梢神経系に影響を及ぼします。このような有病率の増加は、高齢化、遺伝的素因、感染症などの要因によるものです。European Brain Councilが2022年4月に報告したところによると、神経疾患の一つである認知症を患う欧州人の数は、2022年には1,050万人であり、2050年には1,870万人に増加すると予測されています。したがって、神経疾患の有病率の増加は、進行性運動失調と筋力障害市場の重要な促進要因です。

進行性運動失調と筋力障害市場の主要企業は、16歳以上の成人と青年におけるフリードライヒ失調症などの特定の疾患を治療するための経口薬など、革新的な製品の開発に注力しています。経口薬は通常、摂取に便利な錠剤、カプセル剤、液剤の形態で投与されます。例えば、米国のバイオテクノロジー企業であるバイオジェン社は2024年2月、SKYCLARYS（omaveloxolone）がフリードライヒ失調症の治療として欧州委員会から承認を受けたと発表しました。SKYCLARYSは、Nrf2経路を活性化することにより、フリードライヒ失調症の根底にある酸化ストレスとミトコンドリア機能障害に作用します。本薬は食事なしで経口投与され、臨床検査において症状を改善し、疾患の進行を遅らせることで有効性が実証されています。一般的な副作用は、肝酵素の上昇、頭痛、吐き気、腹痛、疲労、下痢、筋骨格痛などがあります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の進行性運動失調と筋力障害 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の進行性運動失調と筋力障害市場：成長率分析
• 世界の進行性運動失調と筋力障害市場の実績：規模と成長、2019～2024年
• 世界の進行性運動失調と筋力障害市場の予測：規模と成長、2024～2029年、2034年
• 世界の進行性運動失調と筋力障害総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の進行性運動失調と筋力障害市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 進行性運動失調症
• 進行性筋力低下障害
• 世界の進行性運動失調と筋力障害市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• 小分子
• モノクローナル抗体
• その他
• 世界の進行性運動失調と筋力障害市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 小売薬局
• 病院薬局
• オンライン薬局
• 世界の進行性運動失調と筋力障害市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• その他
• 世界の進行性運動失調と筋力障害市場、進行性運動失調症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 小脳性運動失調症
• 感覚性運動失調症
• 前庭性運動失調症
• フリードライヒ運動失調症
• 脊髄小脳失調症（SCA）
• 特発性運動失調症
• 世界の進行性運動失調と筋力障害市場、進行性筋力低下障害のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 筋萎縮性側索硬化症（ALS）
• 筋ジストロフィー
• 脊髄性筋萎縮症（SMA）
• 重症筋無力症
• 多発性硬化症（MS）
• ギランバレー症候群（GBS）

第7章 地域別・国別分析

• 世界の進行性運動失調と筋力障害市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の進行性運動失調と筋力障害市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 進行性運動失調と筋力障害市場：競合情勢
• 進行性運動失調と筋力障害市場：企業プロファイル
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• Banner Health
• Astellas Pharma Inc.
• Biogen Inc.
• Daiichi Sankyo Company Limited
• BioMarin Pharmaceutical Inc.
• Sarepta Therapeutics Inc.
• PTC Therapeutics Inc.
• Kissei Pharmaceutical Co. Ltd.
• Biohaven Pharmaceutical Holding Company Ltd.
• Design Therapeutics Inc.
• Anavex Life Sciences Corp.
• Larimar Therapeutics Inc.
• Voyager Therapeutics Inc.
• Stealth BioTherapeutics Corp.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 進行性運動失調と筋力障害市場、2029年：新たな機会を提供する国
• 進行性運動失調と筋力障害市場、2029年：新たな機会を提供するセグメント
• 進行性運動失調と筋力障害市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Progressive ataxia and weakness disorders encompass a range of medical conditions marked by a gradual decline in coordination and muscle strength. These conditions greatly affect a person's quality of life and often necessitate a multidisciplinary approach for accurate diagnosis and effective management.

The primary categories of progressive ataxia and weakness disorders are progressive ataxia and progressive weakness disorders. Progressive ataxia involves a gradual loss of muscle coordination and balance, resulting from degenerative or genetic conditions that impact the cerebellum or other areas of the nervous system. This field includes various technologies, such as small molecules and monoclonal antibodies, which are distributed through multiple channels such as retail pharmacies, hospital pharmacies, and online pharmacies. These treatments are utilized in diverse settings, including hospitals and clinics.

The progressive ataxia and weakness disorders market research report is one of a series of new reports from The Business Research Company that provides progressive ataxia and weakness disorders market statistics, including progressive ataxia and weakness disorders industry global market size, regional shares, competitors with a progressive ataxia and weakness disorders market share, detailed progressive ataxia and weakness disorders market segments, market trends and opportunities, and any further data you may need to thrive in the progressive ataxia and weakness disorders industry. This progressive ataxia and weakness disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The progressive ataxia and weakness disorders market size has grown rapidly in recent years. It will grow from $34.72 billion in 2024 to $38.67 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increasing awareness and diagnosis, growth in genetic research, increasing government funding, increasing expenditures for health care, and a rise in alcohol and drug use.

The progressive ataxia and weakness disorders market size is expected to see rapid growth in the next few years. It will grow to $58.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to the increasing prevalence of neurological disorders, the rising prevalence of chronic diseases, expanding insurance coverage, and the rising aging population. Major trends in the forecast period include technological advancements, genetic testing, gene therapy, personalized medicine, and the adoption of telemedicine.

The increasing prevalence of neurological disorders is expected to drive growth in the market for progressive ataxia and weakness disorders. Neurological disorders affect the central and peripheral nervous systems, encompassing the brain, spinal cord, nerves, and neuromuscular junctions, among others. This rise in prevalence is attributed to factors such as an aging population, genetic predisposition, and infectious diseases. Progressive ataxia and weakness disorders play a crucial role in neurology, guiding diagnosis, treatment, and research efforts aimed at improving outcomes and quality of life for those affected by these challenging conditions. For example, the European Brain Council reported in April 2022 that the number of Europeans with dementia, a neurological condition, was 10.5 million in 2022, projected to increase to 18.7 million by 2050. Therefore, the growing prevalence of neurological disorders is a significant driver for the progressive ataxia and weakness disorders market.

Key companies in the progressive ataxia and weakness disorders market are focused on developing innovative products, such as oral medications for treating specific disorders such as Friedreich's ataxia in adults and adolescents aged 16 years and older. Oral medications are typically administered in tablet, capsule, or liquid form for convenient ingestion. For instance, Biogen Inc., a U.S.-based biotechnology company, announced in February 2024 that SKYCLARYS (omaveloxolone) had received approval from the European Commission for treating Friedreich's ataxia. SKYCLARYS acts by activating the Nrf2 pathway to address oxidative stress and mitochondrial dysfunction underlying Friedreich's ataxia. The medication is taken orally without food and has demonstrated efficacy in clinical trials by improving symptoms and slowing disease progression. Common side effects include elevated liver enzymes, headaches, nausea, abdominal pain, fatigue, diarrhea, and musculoskeletal pain.

In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition was aimed at enhancing Pfizer's position in the pharmaceutical market, particularly in neurology, by expanding its portfolio with Biohaven's investigational drug troriluzole and other treatments for progressive ataxia and weakness disorders. Biohaven Pharmaceutical Holding Company Ltd. specializes in developing therapies for neurological conditions, contributing to Pfizer's capabilities in advancing treatments for these challenging disorders and other therapeutic areas.

Major companies operating in the progressive ataxia and weakness disorders market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Banner Health, Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Kissei Pharmaceutical Co. Ltd., Biohaven Pharmaceutical Holding Company Ltd., Design Therapeutics Inc., Anavex Life Sciences Corp., Larimar Therapeutics Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Capsida Biotherapeutics Inc., Retrotope Inc., Taysha Gene Therapies Inc., CRISPR Therapeutics AG

North America was the largest region in the progressive ataxia and weakness disorders market in 2024. The regions covered in the progressive ataxia and weakness disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the progressive ataxia and weakness disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The progressive ataxia and weakness disorders market consists of revenues earned by entities by providing services such as diagnostic testing, treatment planning, specialized care, and research and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The progressive ataxia and weakness disorders market also includes sales of assistive devices, therapeutic equipment, and diagnostic tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Progressive Ataxia And Weakness Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on progressive ataxia and weakness disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for progressive ataxia and weakness disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The progressive ataxia and weakness disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Progressive Ataxia; Progressive Weakness Disorders
• 2) By Technology: Small Molecule; Monoclonal Antibody; Other Technology
• 3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
• 4) By Application: Hospital; Clinic; Other Applications
• Subsegments:
• 1) By Progressive Ataxia: Cerebellar Ataxia; Sensory Ataxia; Vestibular Ataxia; Friedreich's Ataxia; Spinocerebellar Ataxia (SCA); Idiopathic Ataxia
• 2) By Progressive Weakness Disorders: Amyotrophic Lateral Sclerosis (ALS); Muscular Dystrophy; Spinal Muscular Atrophy (SMA); Myasthenia Gravis; Multiple Sclerosis (MS); Guillain-Barre Syndrome (GBS)
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bristol-Myers Squibb Company; Novartis AG; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Progressive Ataxia And Weakness Disorders Market Characteristics

3. Progressive Ataxia And Weakness Disorders Market Trends And Strategies

4. Progressive Ataxia And Weakness Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Progressive Ataxia And Weakness Disorders Growth Analysis And Strategic Analysis Framework

• 5.1. Global Progressive Ataxia And Weakness Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Progressive Ataxia And Weakness Disorders Market Growth Rate Analysis
• 5.4. Global Progressive Ataxia And Weakness Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Progressive Ataxia And Weakness Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Progressive Ataxia And Weakness Disorders Total Addressable Market (TAM)

6. Progressive Ataxia And Weakness Disorders Market Segmentation

• 6.1. Global Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Progressive Ataxia
• Progressive Weakness Disorders
• 6.2. Global Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule
• Monoclonal Antibody
• Other Technology
• 6.3. Global Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy
• 6.4. Global Progressive Ataxia And Weakness Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Other Applications
• 6.5. Global Progressive Ataxia And Weakness Disorders Market, Sub-Segmentation Of Progressive Ataxia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cerebellar Ataxia
• Sensory Ataxia
• Vestibular Ataxia
• Friedreich's Ataxia
• Spinocerebellar Ataxia (SCA)
• Idiopathic Ataxia
• 6.6. Global Progressive Ataxia And Weakness Disorders Market, Sub-Segmentation Of Progressive Weakness Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amyotrophic Lateral Sclerosis (ALS)
• Muscular Dystrophy
• Spinal Muscular Atrophy (SMA)
• Myasthenia Gravis
• Multiple Sclerosis (MS)
• Guillain-Barre Syndrome (GBS)

7. Progressive Ataxia And Weakness Disorders Market Regional And Country Analysis

• 7.1. Global Progressive Ataxia And Weakness Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Progressive Ataxia And Weakness Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Progressive Ataxia And Weakness Disorders Market

• 8.1. Asia-Pacific Progressive Ataxia And Weakness Disorders Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Progressive Ataxia And Weakness Disorders Market

• 9.1. China Progressive Ataxia And Weakness Disorders Market Overview
• 9.2. China Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Progressive Ataxia And Weakness Disorders Market

• 10.1. India Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Progressive Ataxia And Weakness Disorders Market

• 11.1. Japan Progressive Ataxia And Weakness Disorders Market Overview
• 11.2. Japan Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Progressive Ataxia And Weakness Disorders Market

• 12.1. Australia Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Progressive Ataxia And Weakness Disorders Market

• 13.1. Indonesia Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Progressive Ataxia And Weakness Disorders Market

• 14.1. South Korea Progressive Ataxia And Weakness Disorders Market Overview
• 14.2. South Korea Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Progressive Ataxia And Weakness Disorders Market

• 15.1. Western Europe Progressive Ataxia And Weakness Disorders Market Overview
• 15.2. Western Europe Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Progressive Ataxia And Weakness Disorders Market

• 16.1. UK Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Progressive Ataxia And Weakness Disorders Market

• 17.1. Germany Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Progressive Ataxia And Weakness Disorders Market

• 18.1. France Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Progressive Ataxia And Weakness Disorders Market

• 19.1. Italy Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Progressive Ataxia And Weakness Disorders Market

• 20.1. Spain Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Progressive Ataxia And Weakness Disorders Market

• 21.1. Eastern Europe Progressive Ataxia And Weakness Disorders Market Overview
• 21.2. Eastern Europe Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Progressive Ataxia And Weakness Disorders Market

• 22.1. Russia Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Progressive Ataxia And Weakness Disorders Market

• 23.1. North America Progressive Ataxia And Weakness Disorders Market Overview
• 23.2. North America Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Progressive Ataxia And Weakness Disorders Market

• 24.1. USA Progressive Ataxia And Weakness Disorders Market Overview
• 24.2. USA Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Progressive Ataxia And Weakness Disorders Market

• 25.1. Canada Progressive Ataxia And Weakness Disorders Market Overview
• 25.2. Canada Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Progressive Ataxia And Weakness Disorders Market

• 26.1. South America Progressive Ataxia And Weakness Disorders Market Overview
• 26.2. South America Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Progressive Ataxia And Weakness Disorders Market

• 27.1. Brazil Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Progressive Ataxia And Weakness Disorders Market

• 28.1. Middle East Progressive Ataxia And Weakness Disorders Market Overview
• 28.2. Middle East Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Progressive Ataxia And Weakness Disorders Market

• 29.1. Africa Progressive Ataxia And Weakness Disorders Market Overview
• 29.2. Africa Progressive Ataxia And Weakness Disorders Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Progressive Ataxia And Weakness Disorders Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Progressive Ataxia And Weakness Disorders Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Progressive Ataxia And Weakness Disorders Market Competitive Landscape And Company Profiles

• 30.1. Progressive Ataxia And Weakness Disorders Market Competitive Landscape
• 30.2. Progressive Ataxia And Weakness Disorders Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Progressive Ataxia And Weakness Disorders Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Banner Health
• 31.3. Astellas Pharma Inc.
• 31.4. Biogen Inc.
• 31.5. Daiichi Sankyo Company Limited
• 31.6. BioMarin Pharmaceutical Inc.
• 31.7. Sarepta Therapeutics Inc.
• 31.8. PTC Therapeutics Inc.
• 31.9. Kissei Pharmaceutical Co. Ltd.
• 31.10. Biohaven Pharmaceutical Holding Company Ltd.
• 31.11. Design Therapeutics Inc.
• 31.12. Anavex Life Sciences Corp.
• 31.13. Larimar Therapeutics Inc.
• 31.14. Voyager Therapeutics Inc.
• 31.15. Stealth BioTherapeutics Corp.

32. Global Progressive Ataxia And Weakness Disorders Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Progressive Ataxia And Weakness Disorders Market

34. Recent Developments In The Progressive Ataxia And Weakness Disorders Market

35. Progressive Ataxia And Weakness Disorders Market High Potential Countries, Segments and Strategies

• 35.1 Progressive Ataxia And Weakness Disorders Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Progressive Ataxia And Weakness Disorders Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Progressive Ataxia And Weakness Disorders Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer